The new report by Expert Market Research titled, ‘Global Intraocular Melanoma Treatment Market Growth, Report and Forecast 2021-2026’, gives an in-depth analysis of the global intraocular melanoma treatment market, assessing the market based on its segments like treatment, end use sectors and major regions like Asia Pacific, Europe, North America, Middle East and Africa and Latin America.
The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porter’s Five Forces models.
Request a free sample copy in PDF or view the report summary@
The key highlights of the report include:
Market Overview (2021-2026)
- Historical Market Size
- Forecast CAGR (2020-2026): 7.9%
- Forecast Market Size
The global intraocular melanoma treatment market is primary driven by the rising prevalence of the impact of melanoma on public health. Advances in medications and treatment strategies for intraocular melanoma have resulted in the integration of new solutions for intraocular melanoma treatment. Additionally, the growth is expected to be fueled by increasing awareness of clinical trials to take a closer look at new treatment pathways and therapies and increasing government funding for global disease eradication are also contributing factors. It is also expected that continuing developments in the area of minimally invasive surgery will also contribute to the growth of intraocular melanoma treatment over the forecast period.
Industry Definition and Major Segments
Intraocular melanoma also known as uveal melanoma is the formation of malignant cancer within eyeball specifically iris, choroid, ciliary. The symptoms include blurred vision, light flashes, dark spots, change in pupil size or change is eyeball position within the socket. The prevalence of intraocular melanoma is higher in Caucasian population. The intraocular melanoma metastasizes mainly to liver and is hard to treat. The cause is yet unknown, however UV radiation is a high-risk factor.
Based on treatment, the industry can be divided into the following:
- Surgical Treatment
- Radiation Therapy
- Laser Therapy
- Targeted Therapy
The product finds end-use in the following sectors:
- Specialty Clinics
- Ambulatory Surgical Centres
On the basis of regional markets, the industry is divided into:
1 North America
1.1 United States of America
2.2 United Kingdom
3 Asia Pacific
4 Latin America
5 Middle East & Africa
5.1 Saudi Arabia
5.2 United Arab Emirates
5.4 South Africa
Regionally, North America and Europe are the largest shareholder of global intraocular melanoma treatment market, followed by Europe. This can be attributed to increasing contribution of government and private organizations in developing successful treatment options. Additionally, the advance healthcare facilities, early diagnosis of cancer, new clinical trials, multiple palliative therapies and growing incidences of intraocular melanoma will continue to push the growth for the market in the regions. Meanwhile, increasing prevalence of melanoma cancer in the Asia Pacific region is also expected to propel the growth of the intraocular melanoma treatment market in the said forecast period.
Key Market Players
The major players in the market are AstraZeneca, Pfizer Inc, F. Hoffmann-La Roche Ltd, AbbVie Inc and few others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.